Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Johannesburg Stock Exchange  >  Aspen Pharmacare Holdings Limited    APNJ   ZAE000066692

End-of-day quote. End-of-day quote  - 09/22
312.08 ZAR   +2.76%
09/11ASPEN PHARMACAR : annual earnings release
07/25 ASPEN PHARMACAR : Chamber Anniversaries
05/16 ASPEN PHARMACAR : Eu commission probes aspen cancer drug hikes
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Aspen Pharmacare : to buy remaining AstraZeneca anaesthetic rights for up to $766 million

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2017 | 09:11am CEST
A man walks past a sign at an AstraZeneca site in Macclesfield

AstraZeneca (>> AstraZeneca) said on Thursday it had agreed to sell the U.S. rights to a portfolio of anaesthetics to South Africa's Aspen Group (>> Aspen Pharmacare Holdings Limited) for up to $766 million (579.86 million pounds), a year after Aspen bought the rights outside the United States.

AstraZeneca (>> AstraZeneca) said on Thursday it had agreed to sell the U.S. rights to a portfolio of anaesthetics to South Africa's Aspen Group (>> Aspen Pharmacare Holdings Limited) for up to $766 million (579.86 million pounds), a year after Aspen bought the rights outside the United States.

The British group said it would continue to manufacture and supply the seven medicines - Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest - for a transition period of up to five years.

"Disposing the remaining rights to the medicines allows both companies to benefit from greater efficiencies as AstraZeneca continues to focus our resources on our three main therapy areas," said AstraZeneca executive Mark Mallon.

AstraZeneca is focusing on oncology, cardiovascular and metabolic diseases and respiratory treatments.

It said the deal, which comprises an upfront $555 million and performance related payments of up to $211 million, did not change its financial guidance for 2017.

(Reporting by Paul Sandle; editing by Jason Neely)

Stocks treated in this article : Aspen Pharmacare Holdings Limited, AstraZeneca
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASPEN PHARMACARE HOLDINGS
09/18 ASPEN PHARMACARE : Hits & Misses. Hits. Tshabalala leads Standard alone but SA b..
09/16 Aspen Pharmacare posts 46% profit jump
09/14 ASPEN PHARMACARE : buys remaining rights to AstraZeneca’s anesthetics
09/14 ASPEN PHARMACARE : buys remaining rights to AstraZeneca’s anesthetics
09/11ASPEN PHARMACARE HOLDINGS LIMITED : annual earnings release
08/22 ASPEN PHARMACARE : STOCK WATCH. Aspen hurt by ill winds lashing sector
07/25 ASPEN PHARMACARE : Chamber Anniversaries
06/16 Aspen loses Italy appeal over cancer drug prices
06/15 Cancer drug price increases within allowable limits, says Aspen
06/15 Watchdog probes Aspen for cancer drug pricing
More news
News from SeekingAlpha
05/17 Aspen Pharmacare Has Continued To Grow And Branch Out
2016 Wobbles Aside, Small Pharma Shares Broadly On The Up In 2015
2015 Sector's Smaller Players Show The Way
2015 OPPORTUNITIES AND RISKS IN THE BIOTE : 2 Companies In South Africa
2015 SEEKING ALPHA'S BIOTECH WEEKLY : Deeper Looks At Orexigen, Pharmacyclics, And Ac..
Financials ( ZAR)
Sales 2018 45 958 M
EBIT 2018 11 672 M
Net income 2018 7 854 M
Debt 2018 36 646 M
Yield 2018 1,05%
P/E ratio 2018 17,66
P/E ratio 2019 16,21
EV / Sales 2018 3,90x
EV / Sales 2019 3,58x
Capitalization 142 B
Chart ASPEN PHARMACARE HOLDINGS
Duration : Period :
Aspen Pharmacare Holdings  Technical Analysis Chart | APNJ | ZAE000066692 | 4-Traders
Technical analysis trends ASPEN PHARMACARE HOLDINGS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 326  ZAR
Spread / Average Target 4,5%
EPS Revisions
Managers
NameTitle
Stephen Bradley Saad Group Chief Executive Officer & Executive Director
Douglas Dlamini Chairman
Lorraine Hill Group Operating Officer
Sean Capazorio Group Finance Officer
Michael Guy Attridge Executive Director & Group Deputy CEO
Sector and Competitors